الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - prasata - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogen storage type ii - jiné zažívací trakt a produkty metabolismu, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryho choroba - jiné zažívací trakt a produkty metabolismu, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

جمهورية التشيك - التشيكية - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

laboratorios hipra s.a. - escherichia vakcína + clostridium vakcíny - injekční suspenze - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - prasata - prasnice, prasničky

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

sanofi b.v. - laronidázou - mukopolysacharidóza i - jiné zažívací trakt a produkty metabolismu, - aldurazyme je indikován k dlouhodobé substituční enzymové terapii pacientů s potvrzenou diagnózou mukopolysacharidózy i (mps i; alfa-l-iduronidázy) k léčbě nonneurological projevy onemocnění.

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

sanofi b.v. - agalsidase beta - fabryho choroba - jiné zažívací trakt a produkty metabolismu, - fabrazyme je indikován pro dlouhodobou enzymatickou substituční terapii u pacientů s potvrzenou diagnózou fabryho choroby (nedostatek α-galaktozidázy-a).

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

intervet international b.v. - prasečí circovirus typu 2 orf2 podjednotkový antigen - immunologicals for suidae, inactivated viral vaccines - prasata - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - agalsidáza alfa - fabryho choroba - jiné zažívací trakt a produkty metabolismu, - replagal je indikován k dlouhodobé substituční enzymové terapii pacientů s potvrzenou diagnózou fabryho nemoci (deficience α-galaktosidázy a).

جمهورية التشيك - التشيكية - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

laboratorios hipra s.a. - escherichia vakcína + clostridium vakcíny - injekční suspenze - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - prasata

الاتحاد الأوروبي - التشيكية - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinální stromální nádory - jiná cytostatika, inhibitory proteinkinázy - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.